North America Point Of Care Molecular Testing For Infectious Diseases Market Scope And Analysis

Report Code : TIPRE00039163
Category : Life Sciences

Status : Published
No. of Pages : 162

Buy Now

North America Point-of-Care Molecular Testing for Infectious Diseases Market Scope, Growth, Size and Share by 2031

Buy Now

North America Point-of-Care Molecular Testing for Infectious Diseases Market Report Scope

Report Attribute	Details
Market size in 2023	US$ 1.09 billion
Market Size by 2031	US$ 2.62 billion
Global CAGR (2023 - 2031)	11.5%
Historical Data	2021-2022
Forecast period	2023-2031
Segments Covered	By Diseases HIV Testing Influenza Testing Sexually Transmitted Diseases Testing Hepatitis C Virus Testing Tropical Diseases Testing Respiratory Infection Testing Hospital Acquired Infections Strep By Technology Lateral Flow Assay Dipsticks Microfluidics Molecular Diagnostics Immunoassays Solid Phase By Prescription Testing Prescription Based Testing OTC Testing By Sample Blood Sample Urine Sample Nasal and Oropharyngeal Swabs Sample
Regions and Countries Covered	North America US Canada Mexico
Market leaders and key company profiles	Abbott Laboratories Agilent Technologies Inc Becton Dickinson and Co Bio Rad Laboratories Inc Cardinal Health Inc Danaher Corp Cue Health Inc QuidelOrtho Corp Thermo Fisher Scientific Inc F Hoffmann La Roche Ltd

North America Point-of-Care Molecular Testing for Infectious Diseases Market News and Recent Developments

The North America point-of-care molecular testing for infectious diseases market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the North America point-of-care molecular testing for infectious diseases market are listed below:

Roche received FDA approval for the first molecular test to screen for malaria in blood donors in the US. Roche's cobas Malaria test was approved by the FDA for use on the cobas 6800/8800 Systems. The test identifies infected blood units, making the process of blood donation and transfusion safer. The test screens for the five main species of Plasmodium parasites that cause infection in humans. It can be used to screen blood, organ, and tissue donors, thereby improving blood safety and availability. (Source: QuidelOrtho, Company Website, April 2024)

North America Point-of-Care Molecular Testing for Infectious Diseases Market Report Coverage and Deliverables

The “North America Point-of-Care Molecular Testing for Infectious Diseases Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

North America point-of-care molecular testing for infectious diseases market size and forecast at regional and country levels for all the key market segments covered under the scope
North America point-of-care molecular testing for infectious diseases market trends as well as market dynamics such as drivers, restraints, and key opportunities
Detailed PEST/Porter’s Five Forces and SWOT analysis
North America point-of-care molecular testing for infectious diseases market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the North America point-of-care molecular testing for infectious diseases market.
Detailed company profiles